
Jan 13 (Reuters) - Travere Therapeutics Inc TVTX.O:
TRAVERE THERAPEUTICS ANNOUNCES FDA EXTENDS REVIEW OF SNDA FOR FILSPARI® (SPARSENTAN) IN FSGS
TRAVERE THERAPEUTICS INC - NEW PDUFA TARGET ACTION DATE SET FOR APRIL 13, 2026
TRAVERE THERAPEUTICS INC - NO ADDITIONAL SAFETY OR MANUFACTURING INFO REQUESTED FOR FILSPARI